Daly EJ, et al. - The efficacy, safety, and dose-response of intranasal esketamine hydrochloride were evaluated in patients with treatment-resistant depression (TRD). The antidepressant effect was found to be rapid in onset and dose related. With a lower dosing frequency, the response appeared to persist for more than 2 months. The outcomes supported additional investigation in larger trials.